208 A. Buitrago-Lopez et al., “Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis.” BMJ (Clinical Research Ed.) 343 (January 2011): d4488.

209 G. Desideri et al., “Benefits in cognitive function, blood pressure, and insulin resistance through cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the Cocoa, Cognition, and Aging (CoCoA) study.” Hypertension 60, no. 3 (September 2012): 794–801.

210 B. Buijsse et al., “Cocoa intake, blood pressure, and cardiovascular mortality: the Zutphen Elderly Study.” Archives of Internal Medicine 166, no. 4 (March 2006): 411–17.

211 I. Muraki et al., “Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies.” BMJ (Clinical Research Ed.) 347 (January 2013): f5001.

212 E. E. Devore et al., “Dietary intakes of berries and flavonoids in relation to cognitive decline.” Annals of Neurology 72, no. 1 (July 2012): 135–43.

213 L. Dauchet et al., “Fruit and vegetable consumption and risk of coronary heart disease: a meta-analysis of cohort studies.” Journal of Nutrition 136, no. 10 (October 2006): 2588–93.

214 O. Oyebode et al., “Fruit and vegetable consumption and all-cause, cancer and CVD mortality: analysis of Health Survey for England data.” Journal of Epidemiology and Community Health 68, no. 9 (September 2014): 856–62.

215 C. S. Fuchs et al., “Alcohol consumption and mortality among women.” New England Journal of Medicine 332, no. 19 (May 1995): 1245–50.

216 G. Taubes, Why We Get Fat (New York: Alfred A. Knopf, 2011).

217 A. Stunkard et al., “The results of treatment for obesity: a review of the literature and report of a series.” A.M.A. Archives of Internal Medicine 103, no. 1 (January 1959): 79–85.

218 M. L. Dansinger et al., “Meta-analysis: the effect of dietary counseling for weight loss.” Annals of Internal Medicine 147, no. 1 (July 2007): 41–50.

219 W. L. Haskell et al., “Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association.” Circulation 116, no. 9 (August 2007): 1081–93.

220 M. Fogelholm et al., “Does physical activity prevent weight gain – a systematic review.” Obesity Reviews: An Official Journal of the International Association for the Study of Obesity 1, no. 2 (October 2000): 95–111.

221 I.-M. Lee et al., “Physical activity and weight gain prevention.” JAMA 303, no. 12 (March 2010): 1173–79.

222 P. T. Williams et al., “The effects of changing exercise levels on weight and age-related weight gain.” International Journal of Obesity 30, no. 3 (March 2006): 543–51.

223 R. Dunn, “Everything you know about calories is wrong.” Scientific American 309, no. 3 (September 2013): 56–59.

224 R. U. Almario et al., “Effects of walnut consumption on plasma fatty acids and lipoproteins in combined hyperlipidemia.” American Journal of Clinical Nutrition 74, no. 1 (July 2001): 72–79.

225 M. A. Martínez-González et al., “Nut consumption, weight gain and obesity: epidemiological evidence.” Nutrition, Metabolism, and Cardiovascular Diseases 21 Suppl 1 (June 2011): S40–45.

226 S. Natoli et al., “A review of the evidence: nuts and body weight.” Asia Pacific Journal of Clinical Nutrition 16, no. 4 (January 2007): 588–97.

227 K. K. Ryan et al., “Physiology. Food as a hormone.” Science 339, no. 6122 (March 2013): 918–19.

228 I. A. Munro et al., “Prior supplementation with long chain omega-3 polyunsaturated fatty acids promotes weight loss in obese adults: a double-blinded randomised controlled trial.” Food and Function 4, no. 4 (April 2013): 650–58.

229 F. Bäckhed et al., “The gut microbiota as an environmental factor that regulates fat storage.” Proceedings of the National Academy of Sciences of the United States of America 101, no. 44 (November 2004): 15718–23.

230 N. Alang et al., “Weight gain after fecal microbiota transplantation.” Open Forum Infectious Diseases 2, no. 1 (February 2015): ofv004.

231 D. S. Ludwig et al., “High glycemic index foods, overeating, and obesity.” Pediatrics 103, no. 3 (March 1999): E26.

232 D. B. Pawlak et al., “Effects of dietary glycaemic index on adiposity, glucose homoeostasis, and plasma lipids in animals.” Lancet 364, no. 9436 (January): 778–85.

233 D. S. Ludwig et al., “Increasing adiposity: consequence or cause of overeating?” JAMA 311, no. 21 (June 2014): 2167–68.

234 A. N. Gearhardt et al., “Preliminary validation of the Yale Food Addiction Scale.” Appetite 52, no. 2 (April 2009): 430–36.

235 B. V Howard et al., “Low-fat dietary pattern and weight change over 7 years: the Women’s Health Initiative Dietary Modification Trial.” JAMA 295, no. 1 (January 2006): 39–49.

236 D. E. Thomas et al., “Low glycaemic index or low glycaemic load diets for overweight and obesity.” Cochrane Database of Systematic Reviews 3 (January 2007): CD005105.

237 A. Kekwick et al., “Calorie intake in relation to body-weight changes in the obese.” Lancet 271, no. 6935 (July 1956): 155–61.

238 J. H. Jaap Seidell, Tegenwicht (Bert Bakker, 2011).

239 P. Curtis, “Researchers see bias in private-funded studies.” Guardian, January 8, 2007.

240 W. Willett, “The case for banning trans fats. The FDA’s new policy on these deadly artificial fatty acids is long overdue.” Scientific American 310, no. 3 (March 2014): 13.

241 M. de Lorgeril et al., “Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease.” Lancet 343, no. 8911 (June 1994): 1454–59.

242 S. C. Johnson et al., “mTOR is a key modulator of ageing and age-related disease.” Nature 493, no. 7432 (January 2013): 338–45.

243 A. Bruning, “Inhibition of mTOR signaling by quercetin in cancer treatment and prevention.” Anti-Cancer Agents in Medicinal Chemistry 13, no. 7 (September 2013): 1025–31.

244 A. Reinke et al., “Caffeine targets TOR complex I and provides evidence for a regulatory link between the FRB and kinase domains of Tor1p.” Journal of Biological Chemistry 281, no. 42 (October 2006): 31616–26.

245 G. S. Van Aller et al., “Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor.” Biochemical and Biophysical Research Communications 406, no. 2 (March 2011): 194–99.

246 Y. Kokubo et al., “The impact of green tea and coffee consumption on the reduced risk of stroke incidence in Japanese population: the Japan public health center-based study cohort.” Stroke: A Journal of Cerebral Circulation 44, no. 5 (May 2013): 1369–74.